{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:45:33Z","timestamp":1779115533947,"version":"3.51.4"},"reference-count":63,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.hoc.2011.09.019","type":"journal-article","created":{"date-parts":[[2011,11,18]],"date-time":"2011-11-18T08:50:29Z","timestamp":1321606229000},"page":"1303-1317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Novel Therapeutic Approaches for Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"25","author":[{"given":"Mark R.","family":"Litzow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2011.09.019_bib1","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of acute lymphoblastic leukemia","volume":"354","author":"Pui","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2011.09.019_bib2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1182\/asheducation-2008.1.381","article-title":"The treatment of adults with acute lymphoblastic leukemia","author":"Fielding","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.hoc.2011.09.019_bib3","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2008-06-164863","article-title":"Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century","volume":"113","author":"Pulte","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.019_bib4","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","article-title":"Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial","volume":"109","author":"Moorman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.019_bib5","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","article-title":"What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children\u2019s Cancer Group and Cancer and Leukemia Group B studies","volume":"112","author":"Stock","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.019_bib6","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1182\/asheducation-2009.1.362","article-title":"Evolving paradigms in the therapy of Philadelphia chromosome-negative acute lymphoblastic leukemia in adults","author":"Litzow","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.hoc.2011.09.019_bib7","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/pbc.20776","article-title":"Adolescents with acute lymphoblastic leukaemia: emerging from the shadow of paediatric and adult treatment protocols","volume":"47","author":"Ramanujachar","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.hoc.2011.09.019_bib8","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.hoc.2009.07.002","article-title":"Acute lymphoblastic leukemia in adolescents and young adults","volume":"23","author":"Ribera","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.hoc.2011.09.019_bib9","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1200\/JCO.2003.11.116","article-title":"Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? better doctors? both?","volume":"21","author":"Schiffer","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2011.09.019_bib10","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 Study","volume":"27","author":"Huguet","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2011.09.019_bib11","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1200\/JCO.2007.13.7265","article-title":"Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96","volume":"26","author":"Ribera","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2011.09.019_bib12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2009.07712.x","article-title":"Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen","volume":"146","author":"Storring","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2011.09.019_bib13","series-title":"Phase II study of combination chemotherapy in adolescents and young adults with newly diagnosed acute lymphoblastic leukemia in","year":"2011"},{"key":"10.1016\/j.hoc.2011.09.019_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/asheducation-2010.1.7","article-title":"Minimal residual disease in acute lymphoblastic leukemia","volume":"2010","author":"Campana","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.hoc.2011.09.019_bib15","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1182\/blood.V89.11.3960","article-title":"Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group Study","volume":"89","author":"Borowitz","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.019_bib16","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1182\/blood-2006-04-016709","article-title":"Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia","volume":"108","author":"Jeha","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.019_bib17","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.1182\/blood-2008-04-151860","article-title":"Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia","volume":"113","author":"Thomas","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.019_bib18","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3324\/haematol.2009.010306","article-title":"Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia","volume":"95","author":"Maury","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2011.09.019_bib19","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2011.09.019_bib20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1182\/blood.V116.21.170.170","article-title":"Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+ B-lineage standard and high-risk patients; results of 263 CD20+ patients studied prospectively in GMALL study 07\/2003","volume":"116","author":"Hoelzer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.019_bib21","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/blood-2008-06-164129","article-title":"CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy","volume":"112","author":"Dworzak","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.019_bib22","first-page":"3991s","article-title":"Epratuzumab","volume":"9","author":"Coleman","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2011.09.019_bib23","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.molimm.2006.05.007","article-title":"Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab","volume":"44","author":"Carnahan","year":"2007","journal-title":"Mol Immunol"},{"key":"10.1016\/j.hoc.2011.09.019_bib24","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1182\/blood-2011-02-336990","article-title":"Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma","volume":"118","author":"Micallef","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.019_bib25","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1200\/JCO.2007.15.3528","article-title":"Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children\u2019s Oncology Group Pilot Study","volume":"26","author":"Raetz","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2011.09.019_bib26","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1158\/1078-0432.CCR-09-2980","article-title":"Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial","volume":"16","author":"Wayne","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2011.09.019_bib27","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.V114.22.839.839","article-title":"Phase I clinical trial of the anti-CD22 immunotoxin CAT-8015 (HA22) for pediatric acute lymphoblastic leukemia (ALL)","volume":"114","author":"Wayne","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.019_bib28","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood.V114.22.584.584","article-title":"Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544)\u00a0+ rituximab: clinical activity including survival in patients with recurrent\/refractory follicular or \u2018aggressive\u2019 lymphoma","volume":"114","author":"Dang","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.019_bib29","doi-asserted-by":"crossref","first-page":"420s","DOI":"10.1200\/jco.2011.29.15_suppl.6507","article-title":"Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of greater than 50% in refractory relapse (R-R) acute lymphocytic leukemia (ALL)","volume":"29","author":"Jabbour","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2011.09.019_bib30","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.leukres.2009.02.006","article-title":"Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy","volume":"33","author":"Vallera","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.hoc.2011.09.019_bib31","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1517\/14712598.1.6.1059","article-title":"Alemtuzumab: a novel monoclonal antibody","volume":"1","author":"Keating","year":"2001","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.hoc.2011.09.019_bib32","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/cncr.21901","article-title":"Activity of alemtuzumab in patients with CD52-positive acute leukemia","volume":"106","author":"Tibes","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2011.09.019_bib33","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood.V114.22.838.838","article-title":"Alemtuzumab can be incorporated into front-line therapy of adult acute lymphoblastic leukemia (ALL): final phase I results of a cancer and Leukemia Group B Study (CALGB 10102)","volume":"114","author":"Stock","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.019_bib34","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific T-cell engaging antibodies for cancer therapy","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2011.09.019_bib35","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.hoc.2011.09.019_bib36","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1080\/10428190902943077","article-title":"Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab","volume":"50","author":"Nagorsen","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2011.09.019_bib37","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/blood.V114.22.2723.2723","article-title":"Confirmation of safety, efficacy and response duration in non-Hodgkin lymphoma patients treated with 60 mcg\/m2\/d of BiTE(R) antibody blinatumomab","volume":"114","author":"Nagorsen","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.019_bib38","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2011.09.019_bib39","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.1102160","article-title":"Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia","volume":"306","author":"Weng","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.hoc.2011.09.019_bib40","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1182\/asheducation-2009.1.353","article-title":"The role of NOTCH1 signaling in T-ALL","author":"Ferrando","year":"2009","journal-title":"Hematology"},{"key":"10.1016\/j.hoc.2011.09.019_bib41","doi-asserted-by":"crossref","first-page":"6585","DOI":"10.1200\/jco.2006.24.18_suppl.6585","article-title":"A\u00a0phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia\/lymphoma (T-ALL) and other leukemias","volume":"24","author":"Deangelo","year":"2006","journal-title":"J\u00a0Clin Oncol (Meeting Abstracts)"},{"key":"10.1016\/j.hoc.2011.09.019_bib42","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nm.1900","article-title":"[Gamma]-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia","volume":"15","author":"Real","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2011.09.019_bib43","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1158\/1535-7163.MCT-10-0034","article-title":"Evaluation of selective \u03b3-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design","volume":"9","author":"Wei","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.hoc.2011.09.019_bib44","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1053\/j.seminoncol.2007.11.004","article-title":"Purine nucleoside phosphorylase inhibition as a novel therapeutic approach for B-cell lymphoid malignancies","volume":"34","author":"Furman","year":"2007","journal-title":"Semin Oncol"},{"key":"10.1016\/j.hoc.2011.09.019_bib45","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood.V108.11.1851.1851","article-title":"Forodesine IV (Bcx-1777) is clinically active in relapsed\/refractory T-cell leukemia: results of a phase II study (interim report)","volume":"108","author":"Furman","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.019_bib46","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1200\/JCO.2005.02.998","article-title":"Protein expression of a triad of frequently methylated genes, p73, p57Kip2, and p15, has prognostic value in adult acute lymphocytic leukemia independently of its methylation status","volume":"23","author":"Bueso-Ramos","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2011.09.019_bib47","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1158\/0008-5472.CAN-03-2387","article-title":"Hypermethylation of the 5\u2032 CpG island of the FHIT gene is associated with hyperdiploid and translocation-negative subtypes of pediatric leukemia","volume":"64","author":"Zheng","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2011.09.019_bib48","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.leukres.2004.11.022","article-title":"Antileukemia activity of the combination of 5-aza-2\u2032 -deoxycytidine with valproic acid","volume":"29","author":"Hui","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.hoc.2011.09.019_bib49","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood.V116.21.867.867","article-title":"Final report of a phase I trial of decitabine with or without hyperCVAD in relapsed acute lymphocytic leukemia (ALL)","volume":"116","author":"Garcia-Manero","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.019_bib50","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10637-009-9369-7","article-title":"A\u00a0phase I study of pemetrexed in patients with relapsed or refractory acute leukemia","volume":"29","author":"Abdel-Karim","year":"2011","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.hoc.2011.09.019_bib51","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood.V108.11.1968.1968","article-title":"A\u00a0phase I study of Talvesta(R) (Talotrexin) in relapsed or refractory leukemia or myelodysplastic syndrome","volume":"108","author":"Giles","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.019_bib52","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3324\/haematol.2009.017103","article-title":"Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias","volume":"95","author":"Blum","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2011.09.019_bib53","doi-asserted-by":"crossref","first-page":"8403","DOI":"10.1158\/1078-0432.CCR-05-1201","article-title":"Phase I and pharmacokinetic study of flavopiridol followed by 1-\u03b2 -d-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias","volume":"11","author":"Karp","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2011.09.019_bib54","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/pbc.21214","article-title":"Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program","volume":"50","author":"Houghton","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.hoc.2011.09.019_bib55","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-03-0508","article-title":"Phase I study of bortezomib in refractory or relapsed acute leukemias","volume":"10","author":"Cortes","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2011.09.019_bib56","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1158\/1078-0432.CCR-06-2173","article-title":"A\u00a0phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children\u2019s Oncology Group Study","volume":"13","author":"Horton","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2011.09.019_bib57","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/pbc.22456","article-title":"Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium","volume":"55","author":"Messinger","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.hoc.2011.09.019_bib58","doi-asserted-by":"crossref","first-page":"15113","DOI":"10.1073\/pnas.2436348100","article-title":"Rapamycin is active against B-precursor leukemia in\u00a0vitro and in\u00a0vivo, an effect that is modulated by IL-7-mediated signaling","volume":"100","author":"Brown","year":"2003","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2011.09.019_bib59","doi-asserted-by":"crossref","first-page":"727","DOI":"10.4161\/auto.5.5.8507","article-title":"RAD001 (everolimus) induces autophagy in acute lymphoblastic leukemia","volume":"5","author":"Crazzolara","year":"2009","journal-title":"Autophagy"},{"key":"10.1016\/j.hoc.2011.09.019_bib60","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1182\/blood-2008-02-137752","article-title":"Potentiating effects of RAD001 (everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia","volume":"113","author":"Crazzolara","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.019_bib61","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1038\/leu.2009.171","article-title":"Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells","volume":"23","author":"Hasegawa","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2011.09.019_bib62","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1038\/leu.2009.80","article-title":"MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM","volume":"23","author":"Rambal","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2011.09.019_bib63","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1182\/blood-2009-07-233445","article-title":"A\u00a0small molecule inhibitor of PIM protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia\/lymphoma","volume":"115","author":"Lin","year":"2010","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985881100116X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985881100116X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:57:17Z","timestamp":1760183837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985881100116X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S088985881100116X"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2011.09.019","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Therapeutic Approaches for Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2011.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}